Following initiation of cART, the CD4+ T cell count continues to be monitored because decisions regarding commencement or continuation of prophylaxis against a range of opportunistic infections (OI) are based on the level of immune reconstitution that is achieved; in some resource-limited environments CD4+ testing may be continued to monitor response to cART [2, 3]. The gene discussed is CD4; the disease is Opportunistic infection.